189 related articles for article (PubMed ID: 1338920)
1. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
2. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
4. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
5. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
6. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
7. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
8. [Brain metastases of malignant melanomas].
Boaziz C; Breau JL; Morere JF; Israël L
Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
Siegel R; Hauschild A; Kettelhack C; Kähler KC; Bembenek A; Schlag PM
Eur J Surg Oncol; 2007 Jun; 33(5):627-32. PubMed ID: 17196362
[TBL] [Abstract][Full Text] [Related]
12. [Malignant melanoma of the uvea].
Boaziz C; Mazeron JJ; Morere JF; Breau JL; Israël L
Bull Cancer; 1993 Jul; 80(7):577-83. PubMed ID: 8204938
[TBL] [Abstract][Full Text] [Related]
13. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
Becker JC; Terheyden P; Kämpgen E; Wagner S; Neumann C; Schadendorf D; Steinmann A; Wittenberg G; Lieb W; Bröcker EB
Br J Cancer; 2002 Oct; 87(8):840-5. PubMed ID: 12373596
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603).
Galetta D; Gebbia V; Silvestris N; Ferraù F; Carrozza F; Cigolari S; Russo P; Calista F; Adamo V; Colucci G
Lung Cancer; 2011 Apr; 72(1):59-63. PubMed ID: 20728237
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
[TBL] [Abstract][Full Text] [Related]
16. Complete remission seven years after treatment for metastatic malignant melanoma.
Petit T; Borel C; Rixe O; Avril MF; Monnier A; Giroux B; Weil M; Khayat D
Cancer; 1996 Mar; 77(5):900-2. PubMed ID: 8608481
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
18. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
[TBL] [Abstract][Full Text] [Related]
19. [New toxicity of fotemustine: diffuse interstitial lung disease].
Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
[TBL] [Abstract][Full Text] [Related]
20. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]